Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).

Charlotte L. Zuur,Joris B. W. Elbers,Joris L. Vos,Anne van der Leun,Xiaohang Qiao,Baris Karakullukcu,Michiel W. M. van den Brekel,Bing Tan,Bas Jasperse,Wouter V. Vogel,Laura A. Smit,Stefan M. Willems,Harm van Tinteren,Abrahim Al-Mamgani,Jasper Nijkamp,Ton N. M. Schumacher,Christian U. Blank,J.P. de Boer,John B. A. G. Haanen

Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).

2019

Charlotte L. Zuur
Joris B. W. Elbers
Joris L. Vos
Anne van der Leun
Xiaohang Qiao
Baris Karakullukcu
Michiel W. M. van den Brekel
Bing Tan
Bas Jasperse
Wouter V. Vogel
Laura A. Smit
Stefan M. Willems
Harm van Tinteren
Abrahim Al-Mamgani
Jasper Nijkamp
Ton N. M. Schumacher
Christian U. Blank
J.P. de Boer
John B. A. G. Haanen

2575Background: surgery w/wo adjuvant radiotherapy (RT) for (recurrent) advanced head and neck squamous cell carcinoma (HNSCC) results in 30-50% 5-year OS, indicating the need for novel treatment o...

Keywords:

Physical therapy
Nivolumab
Head and neck cancer
Ipilimumab
Oncology
Toxicity
Medicine
Internal medicine
Head and neck squamous-cell carcinoma
in patient
adjuvant radiotherapy
Pathology
Radiology
salvage surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations